ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,487.03
      0.25%
      US Tech 100
      19,430.40
      0.14%
      Dow Jones
      38,834.86
      0.15%
      Brent Oil
      84.96
      0.21%
      Bitcoin
      65,111.71
      -0.04%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Incyte Corporation (INCY)

      7. Incyte Corporation (INCY) News

      INCY

      Incyte (INCY)

      Incyte Corporation
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:INCY
      DateTimeSourceHeadlineSymbolCompany
      01/18/20242:27PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      01/18/20242:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      01/08/20248:30AMBusiness WireIncyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:INCYIncyte Corporation
      01/05/202412:27PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      01/04/20241:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      01/03/20245:58PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      01/03/20244:06PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INCYIncyte Corporation
      01/03/202412:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      01/03/202412:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      12/14/20232:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      12/13/20234:28PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INCYIncyte Corporation
      12/12/20238:00AMBusiness WireIncyte to Present at Upcoming Investor ConferencesNASDAQ:INCYIncyte Corporation
      12/11/20236:33AMBusiness WireIncyte und Syndax präsentieren bei ASH-Plenarsitzung weitere Daten aus positiver AGAVE-201-Studie, die die Wirksamkeit von Axatilimab zeigen, einschließlich dauerhaftem Ansprechen bei chronischer Graft-versus-Host-KrankheitNASDAQ:INCYIncyte Corporation
      12/10/20235:00PMBusiness WireIncyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host DiseaseNASDAQ:INCYIncyte Corporation
      11/02/20239:00AMBusiness WireIncyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual MeetingNASDAQ:INCYIncyte Corporation
      10/31/20234:02PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INCYIncyte Corporation
      10/31/20237:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INCYIncyte Corporation
      10/31/20237:00AMBusiness WireIncyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical ProgramsNASDAQ:INCYIncyte Corporation
      10/27/20238:00AMBusiness WireScience Magazine Recognizes Incyte as #2 “Top Employer” of 2023NASDAQ:INCYIncyte Corporation
      10/19/20236:06AMIH Market NewsKeep An Eye Out: Pre-Market Movers And Analyst RecommendationsNASDAQ:INCYIncyte Corporation
      10/18/20238:00AMBusiness WireIncyte to Present at Upcoming Investor ConferencesNASDAQ:INCYIncyte Corporation
      10/16/20234:12PMBusiness WireIncyte présentera de nouvelles données issues de son portefeuille d’oncologie au congrès ESMO 2023NASDAQ:INCYIncyte Corporation
      10/16/20234:12PMBusiness WireIncyte kündigt neue Daten aus dem gesamten Onkologie-Portfolio zur Präsentation auf dem ESMO-Kongress 2023 anNASDAQ:INCYIncyte Corporation
      10/16/20238:00AMBusiness WireIncyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023NASDAQ:INCYIncyte Corporation
      10/14/202312:30PMBusiness WireIncyte annonce de nouvelles données pour le ruxolitinib en crème (Opzelura®) dans la dermatite atopique infantileNASDAQ:INCYIncyte Corporation
      10/13/20236:19PMBusiness WireIncyte gibt neue Daten für Ruxolitinib-Creme (Opzelura®®) in atopischer Dermatitis bei Kindern bekanntNASDAQ:INCYIncyte Corporation
      10/13/202310:30AMBusiness WireIncyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic DermatitisNASDAQ:INCYIncyte Corporation
      10/13/20238:00AMBusiness WireData From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)NASDAQ:INCYIncyte Corporation
      10/12/20232:16PMBusiness WireLes nouvelles données à long terme du programme TRuE-V de phase 3 d'Incyte démontrent l'efficacité du traitement prolongé par Opzelura® (Ruxolitinib), une crème destinée aux patients atteints par le vitiligo non segmentaire.NASDAQ:INCYIncyte Corporation
      10/11/20235:21PMBusiness WireNeue Langzeitdaten aus dem Phase 3 TRuE-V Programm von Incyte belegen die Wirksamkeit einer kontinuierlichen Behandlung mit der Opzelura® (Ruxolitinib)-Creme bei nicht-segmentalen Vitiligo-PatientenNASDAQ:INCYIncyte Corporation
       Showing the most relevant articles for your search:NASDAQ:INCY